Kazakh biopharmaceuticals highly valued abroad

Kazakh biopharmaceuticals highly valued abroad

Total revenue from sales of Kazakh innovative products in recent years amounted to 16 billion tenge (US$35.5 million). In particular, domestic biopharmaceuticals are in demand among customers abroad. For example, the Institute of Microbiology and Virology supplies 12 self-developed items to foreign markets. They are intended for medicine, agriculture, food industry, ecology and other sectors of the economy. Doctor of Biology and Member of the National Science Academy Amankeldi Sadanov reported on that at a briefing.

“They also buy our products. Moreover, earlier we supplied foreign analogues. Foreign companies used to sell their drugs, but at present, we can say that we are driving them away from the Kazakh market. The quality of domestic products is much higher when compared to foreign analogues. This is not my opinion, not somebody else’s, but the consumer’s. If the product doesn't deliver real value, no one is going to buy it. I just want to say that to date, we sell billions of products,” said Amankeldi Sadanov, Director General of the Institute of Microbiology and Virology.

Translation by Assem Zhanmukhanova

Editing by Galiya Khassenkhanova